Literature DB >> 6148216

Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen.

P C Ruenitz, J R Bagley, C W Pape.   

Abstract

The triarylethylene antiestrogen tamoxifen (TAM) has been shown to undergo N-demethylation, 4-hydroxylation, and N-oxidation in animals and man. We have studied the effects of drug metabolism inhibitors metyrapone and SKF 525-A, and an inducer (phenobarbital), on these processes and on overall TAM metabolism, in the presence of rat and rabbit liver microsomes. In the rabbit, metyrapone had no significant inhibitory effects. In the rat, it inhibited N-demethylation by 40% at a concentration of 1 microM, while overall TAM metabolism and 4-hydroxylation were unaffected. SKF 525-A markedly inhibited all of these processes in both species. Enzymatic N-oxidation of TAM in the rat was unaffected by either inhibitor, suggesting this to be independent of cytochrome P-450. In the rat, phenobarbital pretreatment increased N-demethylation by 105% and decreased 4-hydroxylation by 48% compared to corresponding rates in untreated animals. Together with the results obtained with the inhibitors, these findings implicate participation of alternative isoenzymatic forms of cytochrome P-450 in N-demethylation and 4-hydroxylation of TAM. In the rat, the sum of the amounts of the three metabolites found was less than the amount of TAM metabolized, implying the existence of additional biotransformation routes. Radiochromatographic analysis of extracts of incubation mixtures showed the presence of the three known metabolites, plus two additional ones. The more polar of these was spectrally and chromatographically identical to authentic 4'-hydroxytamoxifen. The other one, which was slightly less polar than TAM, was tentatively identified as TAM epoxide.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6148216

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.

Authors:  Janet K Coller; Niels Krebsfaenger; Kathrin Klein; Karin Endrizzi; Renzo Wolbold; Thomas Lang; Andreas Nüssler; Peter Neuhaus; Ulrich M Zanger; Michel Eichelbaum; Thomas E Mürdter
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

2.  Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer.

Authors:  D de Vos; P H Slee; D Stevenson; R J Briggs
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

4.  Effects of the antiestrogen toremifene on growth of the human mammary carcinoma cell line MCF-7.

Authors:  R Grenman; K M Laine; P J Klemi; S Grenman; D J Hayashida; H Joensuu
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

5.  Microsomal binding sites for antioestrogens in rat liver. Properties and detergent solubilization.

Authors:  C K Watts; R L Sutherland
Journal:  Biochem J       Date:  1986-06-15       Impact factor: 3.857

Review 6.  Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance.

Authors:  G J Sewell
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

7.  Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.

Authors:  B S Katzenellenbogen; M A Miller; A Mullick; Y Y Sheen
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.